Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications

Aliment Pharmacol Ther. 2018 Feb;47(3):446-447. doi: 10.1111/apt.14435.

Authors

J Côté-Daigneault¹, M L Luong², J-F Colombel³, F Peerani⁴

Affiliations

¹ Division of Gastroenterology, CHUM/CRCHUM, University of Montreal, Quebec, Canada.
² Division of Microbiology and Infectious Diseases, CHUM, University of Montreal, Quebec, Canada.
³ The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine, New York, NY, USA.
⁴ Division of Gastroenterology, University of Alberta, Alberta, Canada.

PMID: 29314127
DOI: 10.1111/apt.14435

No abstract available

Publication types

Letter
Comment

MeSH terms

Herpes Zoster
Humans
Inflammatory Bowel Diseases*
Tumor Necrosis Factor-alpha*
Vaccination

Substances

Tumor Necrosis Factor-alpha